← Back
After treatment and remission

How remission is monitored

Once remission is reached, your team checks regularly that it continues. This topic explains the “levels” of monitoring and what each one shows.

Last updated: ~3 min read
Four translucent rings of light around a calm bone marrow core.
Figure 1.Monitoring has several levels — from the visit to the molecular test.

01Short answer

Remission is monitored on several levels. At each visit the doctor asks about symptoms and examines you, and a blood count and, if needed, biochemistry tests are taken. In some leukaemias a bone marrow test or a measurable residual disease (MRD) test is done at set times — it can find very small numbers of leukaemia cells that ordinary tests miss. Visits are frequent at first, then spread out over the years. The aim is to spot relapse as early as possible while also looking after your overall health. Your doctor builds the exact plan around your disease.

02Simple explanation

Monitoring is not one test but several levels.

The basis is the doctor’s visit and a blood test.

Sometimes a bone marrow or MRD test is needed.

Visits are frequent at first, then less often.

The aim is to spot relapse early.

03Scientific explanation

Schedule: according to the ACS, after AML check-ups are about every 1–3 months for the first 2 years, then less often.

MRD: the 2021 ELN MRD consensus recommends molecular monitoring of blood or marrow after treatment in some AML types (for example NPM1 or CBF).

Bone marrow: some protocols include planned marrow tests even when blood counts are normal; others only when blood counts change.

ALL: according to the ACS, tests are more frequent during maintenance in ALL.

04What happens in the body?

Level one: the doctor’s visit

The doctor asks how you feel and about new symptoms, and checks lymph nodes, liver, spleen and skin. This is the core of follow-up — often the first signal comes from how you feel.

A clinic desk in lamplight with a results folder, a stethoscope and a small plant.
Figure 2.Every visit starts with a conversation and an examination.

Level two: blood tests

The blood count shows how the bone marrow is working. Biochemistry tracks the liver, kidneys and other organs. The doctor looks at the trend in the numbers.

Level three: bone marrow

In some diseases, or when blood counts change, a marrow test is done. It shows the make-up of the cells in the marrow directly.

Level four: molecular and MRD tests

If the leukaemia has a specific marker (such as a gene change), the laboratory can look for it with very sensitive methods. A rising marker may appear before relapse and gives the doctor a chance to act earlier.

A tiny signal fading on a DNA strand among healthy cells.
Figure 3.A molecular test can see even very small numbers of leukaemia cells.

How the schedule changes

In the first years visits are frequent, because the risk of relapse is higher then. Later the gaps grow longer. After several years, follow-up shifts towards general health and late effects.

05The steps of monitoring

Every visit follows the same logic.

Visit — Symptoms and examination.1VisitSymptoms and examination.
Blood tests — Blood count and biochemistry.2Blood testsBlood count and biochemistry.
Marrow if needed — Bone marrow or MRD.3Marrow if neededBone marrow or MRD.
Less often — Visits spread out over the years.4Less oftenVisits spread out over the years.
An early signalChanges are seen in time.
ReassuranceStable results support remission.
A clear scheduleYou know what happens when.

06Levels of monitoring (simplified)

LevelWhat it showsWhen
Doctor’s visitSymptoms, examinationEvery visit
Blood countOverall marrow functionEvery visit
BiochemistryLiver, kidneysOften every visit
Bone marrowCells in the marrowBy protocol or when something changes
MRD / molecular testVery few leukaemia cellsWhen a marker exists, as planned

* The exact schedule depends on the type of leukaemia and your treatment.

07Key terms

Remission
A state in which signs of leukaemia are not detected.
Relapse
The return of the disease after remission.
MRD
Measurable residual disease — leukaemia cells that ordinary methods cannot see.
Marker
A gene or protein feature typical of the leukaemia cell.
Myelogram
A microscopic count of bone marrow cells.
Biochemistry
Blood tests that show how organs are working.

08Key points

  • Monitoring has several levels.
  • The basis is the doctor’s visit and a blood test.
  • Marrow and MRD tests follow a plan.
  • Visits become less frequent over time.
  • If you have symptoms, do not wait.
  • Keep your results in one place.

09Frequently asked questions

Why is marrow not taken every time?

A marrow test is a heavier procedure and not everyone needs it equally often. Your doctor plans it according to the disease and your blood tests.

Is an MRD test done for everyone?

No, only when a suitable marker or method exists. Ask your doctor.

How long will I be followed up?

Usually for years, gradually less often.

What if I miss a visit?

Rebook as soon as possible; continuous follow-up matters.

Can I have tests at another laboratory?

Yes, but send the results to your doctor; use the same laboratory where possible.

10Questions for your doctor

Take these questions to your appointment. The ones you save are collected on the “My questions” page and stay on this device only.

  1. Why is marrow not taken every time?

  2. Is an MRD test done for everyone?

  3. How long will I be followed up?

  4. What if I miss a visit?

  5. Can I have tests at another laboratory?

My questions

12Sources

  1. American Cancer Society. Living as an Acute Myeloid Leukemia (AML) Survivor
  2. American Cancer Society. Living as an Acute Lymphocytic Leukemia Survivor
  3. Blood, 2022. Döhner H et al. Diagnosis and management of AML in adults: 2022 ELN recommendations
  4. Blood, 2021. Heuser M et al. 2021 update on MRD in AML: a consensus document from the ELN MRD Working Party
  5. Leukemia & Lymphoma Society (LLS). Minimal/Measurable Residual Disease
  6. National Cancer Institute (NCI). Follow-Up Medical Care
  7. MedlinePlus (U.S. National Library of Medicine). Complete Blood Count (CBC)
  8. National Cancer Institute (NCI). Survivorship: During and After Treatment
  9. U.S. Food and Drug Administration (FDA). FDA expands approval of Blincyto for treatment of a type of leukemia in patients who have a certain risk factor for relapse
  10. National Cancer Institute (NCI). NCI Dictionary of Cancer Terms: relative survival rate
Medical disclaimerThis information is for educational purposes only and does not replace medical advice.
Last updated: ← Back to the list

Open the interactive site →